Possible Causes of Hiccups in This Clinical Context
In a 56-year-old male with AML on day 2 of 7+3 chemotherapy, the most likely cause of hiccups is dexamethasone used as part of antiemetic prophylaxis, though other chemotherapy-related and disease-related factors must also be considered.
Primary Culprit: Corticosteroid Antiemetics
The most common iatrogenic cause of hiccups during chemotherapy is dexamethasone, which is routinely prescribed as antiemetic prophylaxis during intensive chemotherapy 1, 2. Studies demonstrate that:
- Male patients are disproportionately affected by chemotherapy-induced hiccups, with up to 97.4% of hiccup cases occurring in men receiving platinum-based regimens with dexamethasone 2
- Dexamethasone-induced hiccups typically begin within 24-48 hours of chemotherapy initiation 1
- Discontinuation of dexamethasone in subsequent cycles eliminates hiccups in approximately 90% of cases 2
The timing (day 2) and patient demographics (56-year-old male) in this case strongly suggest dexamethasone as the primary etiology.
Chemotherapy-Related Causes
Cytarabine Toxicity
While cytarabine is a core component of 7+3 induction 3, it rarely causes hiccups directly. However, be vigilant for:
- Cerebellar syndrome: Typically manifests 2-5 days after high-dose cytarabine with dizziness, ataxia, dysarthria, and nausea/vomiting 4
- Risk factors include age >40 years, renal impairment, and high cumulative doses 4
- Standard-dose cytarabine (100-200 mg/m²) used in 7+3 carries lower risk than high-dose regimens 3
Anthracycline Component
The anthracycline (daunorubicin or idarubicin) in 7+3 is not typically associated with hiccups 3.
NK1 Receptor Antagonists
If aprepitant or fosaprepitant was used for antiemetic prophylaxis, this significantly increases hiccup risk:
- Concomitant aprepitant/fosaprepitant increases odds of hiccups (OR: 2.23) 5
- However, aprepitant does not appear to be a major risk factor with high-dose platinum regimens when properly studied 6
Disease-Related Causes
Metabolic Derangements
AML patients receiving intensive chemotherapy are at high risk for:
- Tumor lysis syndrome: Monitor uric acid, phosphate, potassium, calcium, and renal function 3
- Electrolyte abnormalities: Particularly hyponatremia, hypocalcemia, hypomagnesemia
- Uremia: From renal dysfunction secondary to tumor lysis or drug toxicity
CNS Involvement
Consider CNS leukemia, particularly given:
- Monocytic differentiation (M4/M5 morphology)
- WBC >40,000/mcL at diagnosis
- Extramedullary disease 3
If neurologic signs/symptoms are present, obtain brain MRI with contrast and consider lumbar puncture 3.
Infection/Sepsis
Day 2 is early for neutropenic fever, but consider:
- Baseline infection present at diagnosis
- Rapidly developing neutropenia with pre-existing colonization
- Fungal infections (though typically occur later in treatment course) 7
Gastrointestinal Pathology
- Gastric distension from nausea/vomiting
- Esophageal irritation from mucositis (though typically develops later)
- Hepatomegaly from leukemic infiltration causing diaphragmatic irritation
Diagnostic Approach
Immediate assessment should include:
- Medication review: Confirm dexamethasone dosing and timing; identify any NK1 antagonist use
- Metabolic panel: Electrolytes, renal function, calcium, magnesium, phosphate, uric acid
- Neurologic examination: Assess for cerebellar signs (nystagmus, dysmetria, ataxia, slurred speech) 7, 4
- Infection workup: If febrile or clinically unstable
- Consider imaging: Brain MRI if any neurologic symptoms; chest X-ray if respiratory symptoms
Management Strategy
First-Line Intervention
Discontinue or reduce dexamethasone if hiccups are persistent and distressing 1, 2:
- This eliminates hiccups in ~90% of cases 2
- Monitor for breakthrough nausea/vomiting, which may increase but can often be managed with alternative antiemetics 1
- Consider 5-HT3 antagonists alone or with olanzapine as alternative antiemetic strategy 8
Symptomatic Treatment
If dexamethasone cannot be discontinued or hiccups persist:
- Chlorpromazine: Most evidence-based pharmacologic option
- Baclofen: GABA-B agonist, effective for persistent hiccups
- Metoclopramide: Particularly if gastroparesis suspected
- Gabapentin: Alternative for refractory cases
Address Underlying Causes
- Correct electrolyte abnormalities aggressively
- Optimize tumor lysis prophylaxis (hydration, allopurinol/rasburicase) 7
- If cerebellar toxicity develops, discontinue cytarabine immediately and do not rechallenge 7
Critical Pitfalls to Avoid
- Do not automatically attribute hiccups to chemotherapy agents when corticosteroids are the more likely culprit 1
- Do not overlook metabolic derangements in the setting of intensive chemotherapy and high tumor burden
- Do not miss early cerebellar toxicity - perform neurologic assessments before each cytarabine dose 7
- Do not delay workup for CNS leukemia if any neurologic symptoms are present 3
- Monitor for concurrent symptoms - the inverse correlation between hiccups and nausea/vomiting suggests dexamethasone etiology 2